Summit Therapeutics Financial Statements
NASDAQ: SMMTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
17.59+0.42 (+2.45%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Summit Therapeutics revenue and earnings
Summit Therapeutics reported a net loss of $1.08 billion, compared with a loss of $221.3 million a year earlier. Diluted earnings per share came in at -$1.44.
Summary generated from market data by MetaCap's automated system. Methodology
Summit Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-01-31 |
|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 705.00K | 1.81M | 860.00K | 57.09M |
| Revenue growth (YoY) | — | — | -100.00% | -61.03% | +110.35% | -98.49% | — |
| Operating Expenses | 1.09B | 226.00M | 609.65M | 87.21M | 108.96M | 73.36M | 74.31M |
| Research & Development | 537.67M | 150.78M | 59.47M | 52.00M | 85.35M | 53.27M | 52.00M |
| Operating Income | — | -226.00M | -609.65M | -72.09M | -86.19M | -53.19M | 5.39M |
| Interest Expense | 0 | 8.69M | 16.46M | 4.40M | 242.00K | 255.00K | 620.00K |
| Other Income (Expense) | 14.84M | 13.37M | 11.18M | -2.29M | -2.42M | 283.00K | 3.69M |
| Pretax Income | -1.08B | -221.31M | -614.93M | -78.78M | -88.60M | -52.91M | 9.08M |
| Income Tax | 0 | 0 | 0 | — | 0 | -213.00K | -1.79M |
| Net Income | -1.08B | -221.31M | -614.93M | -78.78M | -88.60M | -52.70M | 10.87M |
| Net Income growth (YoY) | — | — | — | — | — | -584.84% | — |
| EPS (Basic) | -1.44 | -0.31 | -0.99 | -0.41 | -0.67 | -0.76 | 0.63 |
| EPS (Diluted) | -1.44 | -0.31 | -0.99 | -0.41 | -0.67 | -0.76 | 0.63 |
| Shares Outstanding (Basic) | 747.70M | 718.54M | 619.65M | 193.34M | 131.71M | 69.52M | 17.14M |
| Shares Outstanding (Diluted) | 747.70M | 718.54M | 619.65M | 193.34M | 131.71M | 69.52M | 17.23M |
| EBITDA | — | -225.91M | -609.45M | -71.74M | -85.86M | -52.89M | 5.80M |
| Operating Margin | — | — | — | -10225.39% | -4764.29% | -6185.23% | 9.44% |
| Net Margin | — | — | — | -11174.75% | -4897.84% | -6127.56% | 19.04% |
This table shows 7 annual periods of Summit Therapeutics's income statement, from FY 2025 back to FY 2019, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow SMMT's reporting calendar. What is a income statement?